volume 2, issue 8, PS536-S537 2007
DOI: 10.1097/01.jto.0000283579.71817.f9
View full text
|
|
Share

Abstract: Background: In lung adenocarcinomas, the Ras signaling pathway is often constitutively activated, and K-Ras activating mutations are widespread. Given the failure in clinical trials of compounds that target

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals